Evidence-gap map · non-drug interventions

Age-Related Macular Degeneration evidence gaps

87 registered non-drug trials, mapped by approach and outcome.

  1. Research Tracker
  2. Evidence-gap maps
  3. Age-Related Macular Degeneration

Which non-drug approaches have been tested for Age-Related Macular Degeneration, and which outcomes they were tested on. An empty cell means no matching trial was found among those searched: a possible gap, not proof that nobody has asked the question.

87registered non-drug trials
10with results posted
12recruiting as of 2026-11-16
28group × outcome cells with at least one trial
⚠️
Research information, not medical advice. These pages index what has been studied in registered trials. A trial existing, completing or posting results says nothing on its own about whether an approach works or is safe for you. Supplements and devices can interact with medicines. Discuss any change with your own clinician.

Evidence-gap matrix

Each number is the count of trials; "with results" is how many of them have posted results on ClinicalTrials.gov. A trial is counted once per group and per outcome domain it covers. The number in brackets after each group is its total trials for this condition.

none1–23–910–2930 or more
Registered non-drug trials for Age-Related Macular Degeneration by intervention group and primary outcome domain
Intervention groupFatigue and energyPost-exertional symptomsCognitionMood, anxiety and wellbeingPainSleepPhysical function and exercise capacityHeart rate, blood pressure and autonomicBreathing and lung functionQuality of lifeWeight and metabolic markersInflammation and other biomarkersSymptom severity and disease activityClinical events, survival and healthcare useFeasibility, adherence and safetyNot classified
Exercise and physical activity (2)···············22 with results
Rehabilitation and therapy services (1)··1·············
Mind-body and psychological approaches (4)··············13
Cognitive training and education (6)···1·····1··1·221 with results
Diet, fasting and nutrition (3)··········1111·1
Neuromodulation and electrical stimulation (6)··············15
Oxygen, light, temperature and manual therapies (16)···········111·151 with results
Supplements and nutraceuticals (30)··1·1··1··31 with results2·34191 with results
Other devices and digital tools (2)······1·······1·
Other behavioural, not yet classified (20)··151 with results·····2·11··124 with results

The table scrolls sideways: 16 outcome columns.

No trials found for this condition in: Breathing and respiratory training; Sleep and circadian approaches; Care delivery and health services.

Where the gaps are

Outcomes not found as a primary outcome in a group's trials

  • Among the 30 trials of supplements and nutraceuticals found, none used mood, anxiety and wellbeing as a primary outcome (6 trials of other approaches did).
  • Among the 16 trials of oxygen, light, temperature and manual therapies found, none used mood, anxiety and wellbeing as a primary outcome (6 trials of other approaches did).
  • Among the 16 trials of oxygen, light, temperature and manual therapies found, none used weight and metabolic markers as a primary outcome (4 trials of other approaches did).
  • Among the 30 trials of supplements and nutraceuticals found, none used quality of life as a primary outcome (3 trials of other approaches did).
  • Among the 30 trials of supplements and nutraceuticals found, none used symptom severity and disease activity as a primary outcome (3 trials of other approaches did).
  • Among the 16 trials of oxygen, light, temperature and manual therapies found, none used cognition as a primary outcome (3 trials of other approaches did).
  • Among the 16 trials of oxygen, light, temperature and manual therapies found, none used quality of life as a primary outcome (3 trials of other approaches did).

Questions studied but with no results posted

  • Supplements and nutraceuticals × feasibility, adherence and safety: 4 trials registered, none with results posted
  • Supplements and nutraceuticals × clinical events, survival and healthcare use: 3 trials registered, none with results posted

Design a trial with DecenTrial (beta) Fund a component of this work

A gap here means no matching trial was found among those searched, not that an approach would work. About one trial in six has primary outcomes the rules cannot classify, so a few gaps may be measured under another name. Some gaps are gaps for good reason.

Most-studied approaches for Age-Related Macular Degeneration

Download this matrix (CSV) Non-drug evidence map Evidence brief RepurpOS condition page Condition page

How outcomes are grouped

Each trial's primary outcome measures are sorted into domains by keyword rules. 58 trials for this condition have primary outcomes the rules could not classify; they appear in the last column rather than being dropped. Checked against 90 hand-labelled outcomes; on a held-out sample of 30, the rules agreed with the hand label for 20 before adjustment, and every outcome they labelled was labelled correctly (misses were left unclassified).

Trial selection and exclusions follow the non-drug evidence map method. Source: ClinicalTrials.gov, searched 2026-11-16.